Posted on 12/19/2022
Now Available in Europe, parts of the Middle East, Asia, Latin America, and Africa
London, UK [November 14, 2022] LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced the continued commercial expansion of its HbA1c test, for professional use across multiple care settings. Used alongside the LumiraDx Platform, the test monitors known diabetic patients’ HbA1c levels and also serves as an aid in screening a...